Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated by Analysts at JMP Securities

JMP Securities began coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note issued on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $17.00 price target on the stock. JMP Securities’ price objective would indicate a potential upside of 124.27% from the stock’s previous close.

Other analysts have also issued reports about the stock. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. Finally, HC Wainwright raised their price objective on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $21.80.

Zevra Therapeutics Stock Down 6.0 %

NASDAQ:ZVRA opened at $7.58 on Tuesday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a 50 day moving average of $7.07 and a 200-day moving average of $5.72. The firm has a market capitalization of $317.25 million, a PE ratio of -5.61 and a beta of 1.94. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same quarter last year, the company posted ($0.15) EPS. Analysts predict that Zevra Therapeutics will post -1.58 EPS for the current year.

Insider Activity at Zevra Therapeutics

In related news, Director Thomas Anderson acquired 10,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were purchased at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders purchased 22,000 shares of company stock worth $140,340 in the last quarter. 2.40% of the stock is owned by company insiders.

Institutional Trading of Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in shares of Zevra Therapeutics during the second quarter valued at $474,000. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares in the last quarter. Retirement Planning Co of New England Inc. increased its holdings in shares of Zevra Therapeutics by 6.5% in the 2nd quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after purchasing an additional 28,107 shares during the period. Mystic Asset Management Inc. lifted its position in shares of Zevra Therapeutics by 11.9% in the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock worth $1,460,000 after purchasing an additional 31,650 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Zevra Therapeutics by 17.9% during the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.